Clinical trials are how new treatments prove they actually work. Understanding them helps you evaluate when treatments are evidence-based and when they're still experimental. In the UK, access to trials varies between NHS and private research.
The trial hierarchy and what evidence actually means
Not all research is equal. A case report of one patient is anecdote. A series of 10 patients is interesting but prone to bias. A randomised controlled trial (RCT) comparing treatment to placebo in hundreds of patients is what changes practice.
Phase 1 trials test safety in small groups (20-100 people) and identify tolerable doses. They're not designed to prove efficacy. Phase 2 trials (100-300 people) look for early signals of benefit. Phase 3 trials (1,000+ people) compare the new treatment to standard treatment or placebo to prove it works.
The key phrase is "randomised controlled." Randomisation means you don't get to choose your treatment—the trial assigns it randomly. This prevents patients who are sicker or more motivated skewing to one group. Controlled means there's a comparison group (standard treatment, placebo, or both).
Meta-analyses pool results from many RCTs. When dozens of trials all show the same thing, that's the strongest evidence. When trials conflict, it suggests the effect is small, depends on patient type, or doesn't exist.
What happens in UK clinical trials
The NHS Research Ethics Service approves trials. Approval is rigorous—the trial must be scientifically sound and risks must be proportional to potential benefit. Participation is always voluntary, and you can withdraw anytime.
NHS trials are free to participants. If you're enrolled in an NHS research study, treatment is covered and you won't be charged. Time and travel are yours to manage, but there's no financial barrier to participation.
Private clinical trials exist in the UK but are less common. These are usually conducted by pharmaceutical companies or research organisations and may offer compensation for time, but they follow the same ethical standards as NHS trials.
Access to trials depends on what's being studied and your location. FindTrial.org is the main registry showing UK clinical trials recruiting now. Ask your consultant if there are relevant trials in your condition—often patients don't know they're available.
When a treatment should still be considered experimental
If there's only Phase 2 data, results are preliminary. Early signals are interesting but often don't hold up in larger trials. Early access programmes (sometimes called "compassionate use") exist for treatments that show early promise but haven't completed Phase 3 trials yet.
Real risks here: the treatment may not work (disappointing but acceptable) or may harm you (serious problem when safety is incompletely known). Early access should be considered only if standard treatment has failed and you understand you're part of active research.
Treatments with no RCT data—common in complementary medicine and some "integrative" clinics—should be considered unproven. That doesn't mean they don't work, but it means no one has shown they work better than placebo in controlled conditions.
Red flags in trial recruitment
Legitimate trials clearly explain risks, benefits, and alternatives. If a trial recruiter downplays risks or creates pressure to enrol, that's a problem. Your written information should be clear and detailed.
Beware trials that exclude standard treatment or require you to stop effective medication. If a trial asks you to stop working cancer drugs to test a new one with no Phase 3 data, the risk calculation needs to be very clear.
Check who's funding the trial. Trials funded by the company making the drug have higher bias toward positive results, though approval standards remain the same. Publicly funded trials (NIHR, Cancer Research UK) have less commercial pressure.
After trial results are published
Published doesn't mean automatically approved. NICE reviews new treatments and decides if the NHS should fund them. This takes time (often 1-2 years after approval) and the answer is sometimes "evidence of benefit is too weak" or "cost per patient is too high."
Ask your consultant: Do the trial results apply to me specifically? A trial showing a new drug helps 40% of patients with a particular genetic marker tells you nothing if you don't have that marker. Context matters more than the headline result.